Table 2.
Characteristics of Trial Population by Asian Race and APAC Region
| Asian Race |
APAC Region |
|||
|---|---|---|---|---|
| Number of Trials Reporting Asian Race >0 | Enrolled Asian Population | Number of Trials Reporting APAC Region >0 | Enrolled APAC Region | |
| Overall | 216/656 (32.9) | 218,613/2,619,710 (8.3) | 109/656 (16.6) | 202,295/2,619,710 (7.7) |
| Trial leaders | ||||
| APAC | 36/52 (69.2) | 116,100/229,275 (50.1) | 36/52 (69.2) | 115,117/229,275 (50.2) |
| Non-APAC | 180/604 (29.8) | 102,513/2,390,435 (4.3) | 73/604 (12.1) | 87,178/2,390,435 (3.6) |
| Disease type | ||||
| Aortic disease | 1/5 (20.0) | 8/3467 (0.2) | 0/5 (0) | 0/3,467 (0) |
| Arrhythmia | 6/48 (12.5) | 1,105/101,929 (1.1) | 8/48 (16.7) | 6,280/101,929 (6.2) |
| CAD | 70/220 (31.8) | 112,262/1,195,769 (9.4) | 42/220 (19.1) | 105,424/1,195,769 (8.8) |
| CeVD | 32/84 (38.1) | 58,506/221,897 (26.4) | 20/84 (23.8) | 54,284/221,897 (24.5) |
| Critical care/resuscitation | 1/24 (4.2) | 646/88,261 (0.7) | 0/24 (0) | 0/8,826 (0) |
| Diabetes | 49/75 (65.3) | 23,990/252,959 (9.5) | 16/75 (21.3) | 10,314/252,959 (4.1) |
| DVT/PE | 5/21 (23.8) | 1,976/39,238 (5.0) | 2/21 (9.5) | 1,509/39,238 (3.8) |
| HF/cardiomyopathy | 23/62 (37.1) | 9,213/97,192 (9.5) | 12/62 (19.4) | 6,448/97,192 (6.6) |
| Hypertension | 6/19 (31.6) | 6,804/61,004 (11.2) | 3/19 (15.8) | 4,239/61,004 (6.9) |
| Lipid disorders | 4/24 (16.7) | 2,226/391,241 (0.6) | 3/24 (12.5) | 11,840/391,241 (3.0) |
| Obesity | 11/32 (34.4) | 369/59,852 (0.6) | 1/32 (3.1) | 851/59,852 (1.4) |
| PAD | 5/14 (35.7) | 1,167/75,672 (1.5) | 1/14 (7.1) | 961/75,672 (1.3) |
| PAH | 2/2 (100.0) | 196/704 (27.8) | 0/2 (0) | 0/704 (0) |
| Pericardial disease | 0/3 (0) | 0/1,880 (0) | 0/3 (0) | 0/1,880 (0) |
| Valvular heart disease | 1/23 (4.4) | 145/28,645 (0.5) | 1/23 (4.3) | 145/28,645 (0.5) |
| Year of publication | ||||
| 2011 | 17/51 (33.3) | 9,353/164,177 (5.7) | 4/51 (7.8) | 4,165/164,177 (2.5) |
| 2012 | 18/62 (29.0) | 8,959/230,462 (3.9) | 3/62 (4.8) | 2,350/230,462 (1.0) |
| 2013 | 15/69 (21.7) | 11,149/467,237 (2.4) | 5/69 (7.2) | 6,806/467,237 (1.5) |
| 2014 | 19/52 (36.5) | 30,936/183,631 (16.8) | 11/52 (21.2) | 38,926/183,631 (21.2) |
| 2015 | 20/75 (26.7) | 34,251/243,081 (14.1) | 15/75 (20.0) | 35,223/243,081 (14.5) |
| 2016 | 17/62 (26.4) | 15,961/172,224 (9.3) | 5/62 (8.1) | 8,525/172,224 (4.9) |
| 2017 | 15/64 (23.4) | 10,485/330,485 (3.2) | 11/64 (17.2) | 19,473/330,485 (5.9) |
| 2018 | 22/69 (31.9) | 36,244/341,165 (10.6) | 18/69 (26.1) | 36,556/341,165 (10.7) |
| 2019 | 40/90 (44.4) | 33,726/336,317 (10.0) | 17/90 (18.9) | 26,606/336,317 (7.9) |
| 2020 | 33/62 (52.2) | 27,549/150,931 (18.3) | 20/62 (32.3) | 23,665/150,931 (15.7) |
| Funding | ||||
| Industry | 132/335 (39.4) | 111,205/1,397,491 (8.0) | 70/335 (20.9) | 98,563/1,397,491 (7.1) |
| Nonindustry | 84/321 (26.2) | 107,408/1,222,219 (8.8) | 39/335 (12.1) | 103,732/1,222,219 (8.5) |
Values are n/N (%).
Abbreviations as in Table 1.